Drug Trial Radar · NCT06161441
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
195
Actual
Start
Jul 16, 2024
Primary completion
Aug 24, 2026
Study completion Nov 4, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * How administering the study drugs might affect quality of life
Conditions
- Resectable Non-small Cell Lung Cancer
Interventions
FianlimabDrug
Administered intravenously (IV) every 3 weeks (Q3W)
CemiplimabDrug
Administered IV Q3W
PemetrexedDrug
Administered IV Q3W
PaclitaxelDrug
Administered IV Q3W
CarboplatinDrug
Administered IV Q3W
CisplatinDrug
Administered IV Q3W
PlaceboDrug
Administered IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samplesTime frame: Up to 24 months
Locations
123 sites in 12 countries. Site status is shown where the registry gives one.
Clermont Oncology Center
Clermont, Florida
University of Illinois
Chicago, Illinois
University of Kansas Cancer Center-Westwood
Westwood, Kansas
Henry Ford Health System
Detroit, Michigan
Mercy South
St Louis, Missouri
University of Rochester
Rochester, New York
Kaiser Permanente Northwest
Portland, Oregon
Virginia Cancer Care Specialist, PC
Fairfax, Virginia
Eastern Health
Box Hill, Victoria, Australia
St Vincent's Hospital
Fitzroy, Victoria, Australia
St John of God Murdoch Hospital
Murdoch, Western Australia, Australia
Orlandi Oncologia
Providencia, Metropolitan Region, Chile
Clinica Santa Maria
Santiago, Providencia, Chile
Centro de Oncologia de Precision
Las Condes, Region Metropolitana, Santiago, Chile
Oncocentro APYS
Viña del Mar, Valparaiso, Chile
APHP - Hopital Ambroise Pare
Boulogne-Billancourt, France
CHU Dijon
Dijon, France
Centre Hospitalier Universitaire de Nantes Hopital Guillaume et Rene Laennec
Nantes, France
Uneos - Hopital R Schuman
Vantoux, France
Centre de Oncologie de Gentilly
Nancy, Grand Est, France
Chi Creteil
Créteil, Île-de-France Region, France
Hopital Cochin
Paris, Île-de-France Region, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, Nantes, France
Centre Hospitalier Universitaire (CHU) Bordeaux
Bordeaux, New Aquitaine, France
CHU Limoges
Limoges, New Aquitaine, France
Cancer Center of Adjara
Batumi, Georgia
Israeli Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Llc Todua Clinic
Tbilisi, Georgia
LTD New Hospitals
Tbilisi, Georgia
High Technology Medical Center, University Clinic Tbilisi
Tbilisi, Georgia
Institute of Clinical Oncology
Tbilisi, Georgia
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
TIM - Tbilisi Institute of Medicine
Tbilisi, Georgia
Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
Klinikum Esslingen
Esslingen am Neckar, Germany
Universitatsklinium Giesse
Giessen, Germany
Asklepios Klinikum Harburg
Hamburg, Germany
Lungenklinik Hemer
Hemer, Germany
MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
Neuss, Germany
LKI LUngenfachklinik Immenhausen
Immenhausen, Hesse, Germany
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.